RxDoctor Payments Data

Asvin Patel, MD

Internal Medicine · Plainview, NYNPI 1255331591

Payments from drug & device makers

$2,789in general payments, 2019–2025

Across 49 payments — averaging $56.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • AstraZeneca$851
  • Johnson & Johnson$492
  • Amarin Pharma, Inc.$136
  • Intuity Medical Inc$121
  • Lilly USA, LLC$30
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$2,789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,789 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$68,111
Medicare patients
74
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$39,671
JanuviaSitagliptin Phosphate17$23,248
FarxigaDapagliflozin Propanediol16$20,411
Metoprolol Succinate93$1,231
Atorvastatin Calcium160$1,123
Lisinopril84$798
Levothyroxine Sodium66$646
Memantine Hcl17$599
Metformin Hcl68$512
Amlodipine Besylate118$503
Simvastatin60$435
Atenolol15$310
Tamsulosin Hcl36$308
Gabapentin11$298
Ezetimibe18$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,123$39,67130 claims
AstraZenecaFarxiga$851$20,41116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →